Tiziana Pharma

Activities: Research & Development Pharmaceutical

Trending Articles

  1. Scleroderma treatment by Certa Therapeutics granted US FDA fast track FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Indian government bans three medicines owing to health risks Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
  4. Dickson achieves ISO 14001 certification ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
  5. The key role of IVDs in healthcare: challenges to commercialisation and access In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and...

Upcoming event

Interphex

16-18 April 2024 | Conference and Exhibition | New York, US See all

Related Content

Research & Development

Tiziana announces positive PET scan results with intranasal Foralumab in patients with na-SPMS

Five out of six patients in FDA authorised expanded access programme are showing a qualitative reduction in microglia activation (a key biomarker being observed)
Manufacturing

Tiziana Life Sciences appoints Chief Development Officer

William A. Clementi will take up the role of Chief Development Officer, which will become effective as of September 1 2023
Research & Development

Tiziana develops novel treatment for COVID-19 patients using anti-interleukin-6-receptor mAbs

Company has filed patent application in support of treatment of COVID-19 utilizing anti-il6r via inhaled delivery
Research & Development

Tiziana strengthens unique research focus by appointing Dr Kunwar Shailubhai CEO
Pharmaceutical

Tiziana Life Sciences appoints Arun Sanyal to its Scientific Advisory Board

Arun Sanyal is a professor and a key opinion leader in liver diseases such as non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
Ingredients

Tiziana Life Sciences in-licenses NI-1201, a fully human anti-IL-6R monoclonal antibody

Exclusive worldwide license expands therapeutic pipeline in key immunological areas
Research & Development

Tiziana acquires bio-repository from Shardna and establishes Sardinian subsidiary LonGevia

Aims to further enhance and develop its portfolio using data from the biobank and genomics research
Subscribe now